Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × COVID-19 × Ivermectin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 1 Coronavirus Infections 1 COVID-19 1

Interventions

BNT162 Vaccine 2 2019-nCoV Vaccine mRNA-1273 2 tocilizumab 1 sotrovimab 1 heterologous prime boost COVID-19 vaccination 1 cilgavimab and tixagevimab drug combination 1 Therapeutics 1 Specimen Handling 1 Sodium Chloride 1 Radiotherapy 1 Losartan 1 Janus Kinase Inhibitors 1 Ivermectin 1 Interleukin-7 1 Hydroxychloroquine 1 HuMax-IL8 1 Ad26COVS1 1 3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid 1 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04447235 2022-08-09

TITAN

Instituto do Cancer do Estado de São Paulo

Phase 2 Terminated

COVID-19, Neoplasms, Coronavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon ⚡